Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Metastatic neuroblastoma
Neuroblastoma
Neuroblastoma differentiation
PTPN1
Protein tyrosine phosphatases
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
14 Dec 2019
14 Dec 2019
Historique:
received:
15
10
2019
accepted:
06
12
2019
entrez:
16
12
2019
pubmed:
16
12
2019
medline:
4
6
2020
Statut:
epublish
Résumé
Protein tyrosine phosphatases (PTPs) regulate neuronal differentiation and survival, but their expression patterns and functions in human neuroblastoma (NB) are scarcely known. Here, we have investigated the function and expression of the non-receptor PTPN1 on human NB cell lines and human NB tumor samples. NB tumor samples from 44 patients were analysed by immunohistochemistry using specific antibodies against PTPN1, PTPRH, PTPRZ1, and PTEN. PTPN1 knock-down, cell proliferation and tyrosine phosphorylation analyses, and RT-qPCR mRNA expression was assessed on SH-SY5Y, SMS-KCNR, and IMR-32 human NB cell lines. Knock-down of PTPN1 in SH-SY5Y NB cells resulted in increased tyrosine phosphorylation and cell proliferation. Retinoic acid-mediated differentiation of NB cell lines did not affect PTPN1 mRNA expression, as compared with other PTPs. Importantly, PTPN1 displayed high expression on NB tumors in association with metastasis and poor prognosis. Our results identify PTPN1 as a candidate regulator of NB cell growth and a potential NB prognostic biomarker.
Sections du résumé
BACKGROUND
BACKGROUND
Protein tyrosine phosphatases (PTPs) regulate neuronal differentiation and survival, but their expression patterns and functions in human neuroblastoma (NB) are scarcely known. Here, we have investigated the function and expression of the non-receptor PTPN1 on human NB cell lines and human NB tumor samples.
MATERIAL/METHODS
METHODS
NB tumor samples from 44 patients were analysed by immunohistochemistry using specific antibodies against PTPN1, PTPRH, PTPRZ1, and PTEN. PTPN1 knock-down, cell proliferation and tyrosine phosphorylation analyses, and RT-qPCR mRNA expression was assessed on SH-SY5Y, SMS-KCNR, and IMR-32 human NB cell lines.
RESULTS
RESULTS
Knock-down of PTPN1 in SH-SY5Y NB cells resulted in increased tyrosine phosphorylation and cell proliferation. Retinoic acid-mediated differentiation of NB cell lines did not affect PTPN1 mRNA expression, as compared with other PTPs. Importantly, PTPN1 displayed high expression on NB tumors in association with metastasis and poor prognosis.
CONCLUSIONS
CONCLUSIONS
Our results identify PTPN1 as a candidate regulator of NB cell growth and a potential NB prognostic biomarker.
Identifiants
pubmed: 31837707
doi: 10.1186/s13000-019-0919-9
pii: 10.1186/s13000-019-0919-9
pmc: PMC6911276
doi:
Substances chimiques
Biomarkers, Tumor
0
PTPN1 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 1
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Subventions
Organisme : BIOEF (EITB maratoia)
ID : BIO13/CI/001/BC
Organisme : Ministerio de Educación y Ciencia
ID : SAF2013-48812-R
Organisme : Ministerio de Economía y Competitividad
ID : SAF2016-79847-R
Organisme : The Research Council of Norway
ID : 239813
Références
World J Clin Oncol. 2015 Dec 10;6(6):212-5
pubmed: 26677433
FEBS J. 2013 Jan;280(2):708-30
pubmed: 22938156
Pediatr Hematol Oncol. 2017 Apr;34(3):165-185
pubmed: 28662353
Drug Discov Today. 2007 May;12(9-10):373-81
pubmed: 17467573
Children (Basel). 2018 Aug 28;5(9):null
pubmed: 30154341
Cancers (Basel). 2018 Apr 10;10(4):null
pubmed: 29642598
Cancer Chemother Pharmacol. 2015 Jan;75(1):131-41
pubmed: 25394774
Exp Mol Pathol. 2018 Dec;105(3):272-278
pubmed: 30171833
Dev Biol. 2017 Aug 15;428(2):283-292
pubmed: 28728679
Cancer Cell. 2012 Jul 10;22(1):117-30
pubmed: 22789543
Cancer Res. 1992 Aug 15;52(16):4402-7
pubmed: 1322787
FEBS J. 2013 Jan;280(2):346-78
pubmed: 23176256
Cancer Lett. 2015 Feb 1;357(1):316-327
pubmed: 25444896
Trends Biochem Sci. 2010 Aug;35(8):442-9
pubmed: 20381358
Clin Cancer Res. 2009 May 15;15(10):3244-50
pubmed: 19417027
Nat Genet. 2007 Mar;39(3):338-46
pubmed: 17259984
Cell Signal. 2013 Jun;25(6):1505-13
pubmed: 23499906
J Biol Chem. 2012 Jan 27;287(5):3433-44
pubmed: 22117074
Curr Opin Pediatr. 2016 Feb;28(1):19-25
pubmed: 26576010
Nat Rev Clin Oncol. 2012 May 15;9(7):391-9
pubmed: 22585002
Cell Tissue Res. 2018 May;372(2):277-286
pubmed: 29305654
Cancer Sci. 2011 Feb;102(2):302-8
pubmed: 21205076
J Clin Oncol. 2014 Oct 1;32(28):3169-76
pubmed: 25154816
Methods Mol Biol. 2016;1447:25-37
pubmed: 27514798
Cell Tissue Res. 2018 May;372(2):287-307
pubmed: 29589100
Exp Cell Res. 1983 Oct;148(1):21-30
pubmed: 6313408
Endocrinology. 2009 Mar;150(3):1182-91
pubmed: 19008309
Children (Basel). 2018 Oct 31;5(11):null
pubmed: 30384486
Cell Tissue Res. 2018 May;372(2):325-337
pubmed: 29374774
Semin Cancer Biol. 2011 Oct;21(4):276-82
pubmed: 21945591
Cell Differ. 1984 Jun;14(2):135-44
pubmed: 6467378
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Cell Cycle. 2015;14(5):732-43
pubmed: 25590580
Methods Mol Biol. 2016;1447:1-23
pubmed: 27514797
Biochim Biophys Acta. 2013 Oct;1832(10):1673-96
pubmed: 23707412
Crit Rev Biochem Mol Biol. 2013 Sep-Oct;48(5):430-45
pubmed: 23879520
J Biol Chem. 2014 Nov 14;289(46):31682-92
pubmed: 25288805
Cancer Lett. 2015 Apr 10;359(2):218-25
pubmed: 25617799
Cancer Lett. 2013 Jan 1;328(1):44-54
pubmed: 23022267
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
FEBS Lett. 2003 Jul 3;546(1):140-8
pubmed: 12829250
Cold Spring Harb Perspect Biol. 2014 May 01;6(5):a020644
pubmed: 24789824
Expert Opin Investig Drugs. 2017 Nov;26(11):1281-1293
pubmed: 28906153
J Mol Histol. 2014 Apr;45(2):153-9
pubmed: 23990346
Pol J Pathol. 2010;61(4):192-8
pubmed: 21290341
Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75
pubmed: 28253830
Clin Cancer Res. 2010 Sep 1;16(17):4353-62
pubmed: 20719933
Cell Tissue Res. 2018 May;372(2):211-221
pubmed: 29445860
Int J Cancer. 2004 May 1;109(5):673-9
pubmed: 14999773
Clin Cancer Res. 2012 May 1;18(9):2423-8
pubmed: 22427348